Andere talen Lumosa Therapeutics Co., Ltd.

Aandelen

6535

TW0006535008

slotkoers Taipei Exchange Andere beurzen 00:00:00 03-05-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
170 ^TWD	-1,45%		-1,16%	+148,90%

01/04	Lumosa Therapeutics Co, Ltd. Rapporteert winstresultaten voor het volledige jaar eindigend op 31 december 2023	CI
02/02	Lumosa Therapeutics en CHI Memorial kondigen nieuwe studie aan voor acute beroerte	CI

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

Lumosa Therapeutics Co., Ltd. cancelled the transaction announced on May 31, 2023	24/04
GenEditBio Limited announced that it has received funding from Lumosa Therapeutics Co., Ltd., Qiming Weichuang Venture Capital Management Company Limited, Innovation & Technology Fund Company, Hong Kong Science and Technology Parks, Investment Arm	07/04
Lumosa Therapeutics Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	01/04
Lumosa Therapeutics and CHI Memorial Announce New Study for Acute Stroke	02/02
Lumosa Therapeutics Co., Ltd. Receives Approval to Initiate Phase 2, Multiple-Dose Study of Its LT3001	22/01
Lumosa Therapeutics Co., Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	10/11
Lumosa Therapeutics Co., Ltd. Approves the Exclusive Licensing Agreement with Gufic Biosciences for LT1001, A Long-Acting Analgesic Injection	09/11
Lumosa Therapeutics Co., Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	09-08-23
Lumosa Therapeutics Co., Ltd. Approves Formulation Patent for Lumosas Lt3001, A New Drug for Acute Ischemic Stroke	26-07-23
Lumosa Therapeutics Co., Ltd. Appoints Hsin-Jung Lin as Member of the Audit Committee	31-05-23
Lumosa Therapeutics Co., Ltd. Announces Appointment of Hsin-Jung Lin as Independent Director	31-05-23
Lumosa Therapeutics Co., Ltd. announced a financing transaction	31-05-23
Lumosa Therapeutics Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023	15-05-23
Lumosa Therapeutics Co., Ltd. Appoints Lanying Huang as Corporate Governance Officer	12-05-23
Lumosa Therapeutics Co., Ltd. announced a financing transaction	10-03-23
Lumosa Therapeutics Co., Ltd. Approves Exclusive Licensing Agreement with Pakistan’s AJM Pharma Pvt. Ltd. for LT1001, A Long-Acting Analgesic Injection	23-12-22
Lumosa Therapeutics Co., Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	10-11-22
Lumosa Therapeutics : Board Approved the Revised Exclusive Licensing Agreement for the Veterinary Analgesic	09-08-22
Lumosa Therapeutics : Board Approved the Binding Term Sheet for LT1001, a Long-acting Analgesic Injection, with a Pakistani Pharmaceutical Company	09-08-22
Lumosa Therapeutics : Board of Directors approved the Cancellation of Restricted Shares to Employees Stock Awards	09-08-22

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen Lumosa Therapeutics Co., Ltd.

Aandelen

6535

TW0006535008

Andere talen

Filters